Stevanato Group S.p.A. (STVN) stock analysis
Close on Nov 12, 2026Market cap $4.35BP/E 25.2Yield –
StockData Score
Prices as of Nov 11, 2026How the score works
Weak8 of 30 checks passed
Stevanato Group S.p.A. passes 8 of the 30 checks behind our score; 16 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 2/6
- Past performance
- 4/6
- Financial health
- 2/6
- Dividend
- 0/6
What stands out
Return on capital over 10%
Return on invested capital was 11.0%, above the 10% that usually covers the cost of capital.
Earnings grew over 5 years
Net income grew 12.2% a year on average over the last five fiscal years.
Earnings growth accelerating
Net income grew 18.7% over the last twelve months, against a 5-year average of 12.2% a year.
Interest well covered
Operating income covers interest expense 8.8 times.
What to watch
Return on equity under 15%
Return on equity was 9.7% over the last twelve months and averaged 14.3% over five years; we look for 15% on both.
Revenue growing under 10% a year
Revenue grew 6.4% a year over the last three fiscal years, short of the 10% we look for.
EPS growing under 10% a year
Diluted EPS grew -1.9% a year over the last three fiscal years.
Growing slower than the industry
Revenue grew 7.4% over the last twelve months; the Surgical, Medical, and Dental Instruments and Supplies median is 11.0%.
Valuation0/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B against the industry
Needs positive book value.
Price against fair value
We could not estimate a fair value: it needs at least two valuation methods with positive inputs.
Margin of safety
Depends on the fair value estimate.
Growth2/6
Revenue growing under 10% a year
Revenue grew 6.4% a year over the last three fiscal years, short of the 10% we look for.
EPS growing under 10% a year
Diluted EPS grew -1.9% a year over the last three fiscal years.
Earnings growth accelerating
Net income grew 18.7% over the last twelve months, against a 5-year average of 12.2% a year.
Growing slower than the industry
Revenue grew 7.4% over the last twelve months; the Surgical, Medical, and Dental Instruments and Supplies median is 11.0%.
Guidance issued
The latest outlook (FY 2026 Revenue at Constant Currency, Mar 4, 2026) was issued for the first time, so it neither adds nor takes away points.
Gross margin improving
Gross margin was 29.0% over the last twelve months, against 27.4% a year earlier.
Past performance4/6
Return on equity under 15%
Return on equity was 9.7% over the last twelve months and averaged 14.3% over five years; we look for 15% on both.
Return on capital over 10%
Return on invested capital was 11.0%, above the 10% that usually covers the cost of capital.
Return on equity above the industry
Stevanato Group S.p.A.'s return on equity of 9.7% is above the Surgical, Medical, and Dental Instruments and Supplies median of -31.3%.
Earnings grew over 5 years
Net income grew 12.2% a year on average over the last five fiscal years.
Net margin below its 5-year average
Net margin was 11.8% over the last twelve months, against a 5-year average of 13.3%.
Net margin above the industry
Stevanato Group S.p.A.'s net margin of 11.8% is above the Surgical, Medical, and Dental Instruments and Supplies median of -14.1%.
Financial health2/6
Debt level
Needs debt and equity figures.
Debt trend
Needs a balance sheet from five years ago with positive equity.
Debt coverage
Needs operating cash flow.
Interest well covered
Operating income covers interest expense 8.8 times.
Short-term assets cover short-term debts
Current assets are 1.76 times current liabilities.
Bankruptcy risk (Altman Z)
Needs market value, working capital and retained earnings.
Dividend0/6
No dividend
Stevanato Group S.p.A. has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itWe don't publish a fair value for Stevanato Group S.p.A.. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Medium risk
- Average value traded per day
- $13.74M
- Value traded per 1% price move
- $4.22M
Downside
High risk
- Typical loss in a bad month
- 30.1%
- Volatility (annualized)
- 54%
- Sharpe ratio, 1 year
- -0.87
- Beta to the S&P 500 (5Y)
- 0.92
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2018 to 2025
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +7.4% | +6.4% | +12.4% | – | |
| Gross profit | +13.7% | +2.4% | +12.1% | – | |
| Operating income | +23.4% | +1.1% | +14.0% | – | |
| Net income | +18.7% | -0.7% | +12.2% | – | |
| EPS, diluted | +18.6% | -1.9% | +9.1% | – | |
| Free cash flow | – | – | -19.5% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | 9.7% | |
| Return on assets | – | – | 5.7% | |
| Current ratio | – | 1.56 | 1.76 | |
| Interest coverage | – | 4.7× | 8.8× | |
| Inventory turnover | – | – | 3.3× | |
| Capex to revenue | – | 13.5% | 22.2% | |
| Diluted shares | – | 241M | 273M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Stevanato Group S.p.A. generated €783.71M from operations and spent €1.41B on capital expenditure, dividends and share buybacks. 95% of that went back into the business.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 11.8% | 0.49× | 1.69× | 9.7% |
| FY2024 | 10.7% | 0.50× | 1.73× | 9.3% |
| FY2023 | 13.4% | 0.58× | 1.75× | 13.7% |
| FY2022 | 14.5% | 0.64× | 1.67× | 15.5% |
| FY2021 | 15.9% | 0.71× | 2.07× | 23.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero€139.84M
- Cash generatingOperating cash flow above zero€286.08M
- Return on assets improvedROA up on the prior year5.7% → 6.0%
- Earnings backed by cashOperating cash flow above net income€286.08M vs €139.84M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.84 → 1.76
- No dilutionShare count did not rise271M → 273M
- Gross margin improvedGross margin up on the prior year27.38% → 28.99%
- More efficientAsset turnover rose0.53 → 0.51
See a number that looks wrong?